Biophagy is a biopharmaceutical company focused on enhancing the body's natural defenses against diseases and the effects of aging through innovative drug development. The company is dedicated to creating targeted, proprietary drugs that modulate autophagy, a cellular process crucial for maintaining health and combating various diseases. Their proprietary drug development program emphasizes anti-infectives and neurodegenerative diseases, with the aim of advancing lead compounds into pre-clinical development before partnering with larger firms for further testing and clinical trials. Biophagy's patented chemical libraries include compounds that have shown activity against neurodegenerative diseases, tuberculosis, and SARS-CoV-2.

In addition to drug development, Biophagy offers a personalized health solution called CellWatch™, which combines a tailored formulation with a diagnostic kit to help individuals monitor and enhance their autophagy function. This dual approach not only targets significant medical needs through drug development but also empowers individuals to take charge of their health by measuring the effectiveness of their autophagy enhancement strategies. Collaborations with esteemed institutions such as Sandia National Laboratories and the University of New Mexico further bolster Biophagy's research and development efforts, positioning the company as a leader in the biopharmaceutical landscape.

United States

Biophagy is a biopharmaceutical company, headquartered at The BioScience Center, Albuquerque, NM, USA. The company is focused on identifying drugs that modulate autophagy as part of a specific disease process in order to relieve patient symptoms. Biophagy is managing standard drug development programs in several therapeutic areas and is also developing an OTC/DTC kit that will focus on autophagy stimulation and measurement.

Biophagy

Company Details